Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Only 12 Evaluable Patients at 450 days 67% CR !!!!!!

<< Previous

Bullboard Posts

Next >>

Comment by riverrrowon Apr 26, 2023 9:21pm

192 Views

Post# 35416045

RE:RE:Only 12 Evaluable Patients at 450 days 67% CR !!!!!!

So is the bottom line that TLT now has enough patients reaching 450 days that were treated correctly with the right dose for the results to be statistically significant? TLT can now drop those patients that were under dosed and Phase 1 patients that didn't really meet the trial protocol. While the 67% seems astronomical, on a science level it makes sense to me. Also, don't forget the 2 out of 3 patients from phase 1 that were CR at 450 days, ie 67%.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China